Taiwan · Delayed Price · Currency is TWD OK Biotech Statistics
Total Valuation
OK Biotech has a market cap or net worth of TWD 1.99 billion. The enterprise value is 2.71 billion.
| Market Cap | 1.99B |
| Enterprise Value | 2.71B |
Important Dates
The last earnings date was Wednesday, August 12, 2026.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | Jul 4, 2025 |
Share Statistics
OK Biotech has 137.17 million shares outstanding. The number of shares has increased by 3.21% in one year.
| Current Share Class | 137.17M |
| Shares Outstanding | 137.17M |
| Shares Change (YoY) | +3.21% |
| Shares Change (QoQ) | -0.92% |
| Owned by Insiders (%) | 5.07% |
| Owned by Institutions (%) | 0.30% |
| Float | 101.34M |
Valuation Ratios
The trailing PE ratio is 8.67.
| PE Ratio | 8.67 |
| Forward PE | n/a |
| PS Ratio | 1.29 |
| PB Ratio | 0.77 |
| P/TBV Ratio | 0.97 |
| P/FCF Ratio | 7.92 |
| P/OCF Ratio | 4.05 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.60, with an EV/FCF ratio of 10.77.
| EV / Earnings | 11.17 |
| EV / Sales | 1.76 |
| EV / EBITDA | 8.60 |
| EV / EBIT | 12.09 |
| EV / FCF | 10.77 |
Financial Position
The company has a current ratio of 2.40, with a Debt / Equity ratio of 0.41.
| Current Ratio | 2.40 |
| Quick Ratio | 1.51 |
| Debt / Equity | 0.41 |
| Debt / EBITDA | 3.35 |
| Debt / FCF | 4.16 |
| Interest Coverage | 22.33 |
Financial Efficiency
Return on equity (ROE) is 10.29% and return on invested capital (ROIC) is 5.96%.
| Return on Equity (ROE) | 10.29% |
| Return on Assets (ROA) | 3.59% |
| Return on Invested Capital (ROIC) | 5.96% |
| Return on Capital Employed (ROCE) | 6.44% |
| Weighted Average Cost of Capital (WACC) | 3.94% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.40 |
| Inventory Turnover | 2.25 |
Taxes
In the past 12 months, OK Biotech has paid 34.95 million in taxes.
| Income Tax | 34.95M |
| Effective Tax Rate | 11.92% |
Stock Price Statistics
The stock price has decreased by -10.43% in the last 52 weeks. The beta is 0.24, so OK Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.24 |
| 52-Week Price Change | -10.43% |
| 50-Day Moving Average | 15.07 |
| 200-Day Moving Average | 14.48 |
| Relative Strength Index (RSI) | 44.53 |
| Average Volume (20 Days) | 225,263 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, OK Biotech had revenue of TWD 1.54 billion and earned 242.24 million in profits. Earnings per share was 1.67.
| Revenue | 1.54B |
| Gross Profit | 478.56M |
| Operating Income | 220.22M |
| Pretax Income | 293.10M |
| Net Income | 242.24M |
| EBITDA | 300.14M |
| EBIT | 220.22M |
| Earnings Per Share (EPS) | 1.67 |
Balance Sheet
The company has 382.88 million in cash and 1.04 billion in debt, with a net cash position of -661.02 million or -4.82 per share.
| Cash & Cash Equivalents | 382.88M |
| Total Debt | 1.04B |
| Net Cash | -661.02M |
| Net Cash Per Share | -4.82 |
| Equity (Book Value) | 2.57B |
| Book Value Per Share | 18.35 |
| Working Capital | 801.56M |
Cash Flow
In the last 12 months, operating cash flow was 491.18 million and capital expenditures -239.94 million, giving a free cash flow of 251.23 million.
| Operating Cash Flow | 491.18M |
| Capital Expenditures | -239.94M |
| Depreciation & Amortization | 77.76M |
| Net Borrowing | 71.13M |
| Free Cash Flow | 251.23M |
| FCF Per Share | 1.83 |
Margins
Gross margin is 31.13%, with operating and profit margins of 14.33% and 15.76%.
| Gross Margin | 31.13% |
| Operating Margin | 14.33% |
| Pretax Margin | 19.07% |
| Profit Margin | 15.76% |
| EBITDA Margin | 19.53% |
| EBIT Margin | 14.33% |
| FCF Margin | 16.34% |
Dividends & Yields
This stock pays an annual dividend of 0.30, which amounts to a dividend yield of 2.05%.
| Dividend Per Share | 0.30 |
| Dividend Yield | 2.05% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 18.08% |
| Buyback Yield | -3.21% |
| Shareholder Yield | -1.16% |
| Earnings Yield | 12.18% |
| FCF Yield | 12.63% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 6, 2023. It was a forward split with a ratio of 1.10213412.
| Last Split Date | Sep 6, 2023 |
| Split Type | Forward |
| Split Ratio | 1.10213412 |
Scores
OK Biotech has an Altman Z-Score of 1.8 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.8 |
| Piotroski F-Score | 6 |